Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, double-blind, randomized, placebo-controlled study of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe lateral canthal lines (LCLs) at maximum smile

Trial Profile

A Phase III, double-blind, randomized, placebo-controlled study of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe lateral canthal lines (LCLs) at maximum smile

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Sep 2018 New trial record
    • 14 Aug 2018 According to a Galderma media release, Health Canada has approved DYSPORT AESTHETIC (abobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's feet) in adult patients, based on the data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top